Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as RO7425781
Forimtamig · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part I: Dose Escalation | EXPERIMENTAL | Participants will receive forimtamig as intravenous (IV) infusion and/or subcutaneous (SC) injection in a step-up dosing fashion. |
| Part II: Dose Expansion | EXPERIMENTAL | Dose Expansion cohorts with IV and/or SC administration, respectively, will be initiated at the Recommended Phase 2 Doses (RP2Ds) determined in Part I: Dose Escalation phase. |
| Name | Type | Description |
|---|---|---|
| Forimtamig | DRUG | Forimtamig will be administered via IV/SC administration. The RP2Ds determined during Part I: Dose Escalation will be administered during Part II: Dose Expansion. Forimtamig will be administered as per the dosing schedule defined in Part I. |
Inclusion Criteria: * Previously diagnosed with Multiple Myeloma (MM) based on standard criteria. * Dose Escalation Phase and Dose Expansion Phase: Participants with r/r MM who have previously received therapy with an Immunomodulatory drug (IMiD) and Proteasome Inhibitor (PI) and are intolerant to ...
Top 20 of 25 competitors
Forimtamig is an investigational therapy being studied for relapsed or refractory multiple myeloma, a cancer of plasma cells in the bone marrow. It is not approved for any indication and remains in clinical development. The Phase 1 study enrolled adults with relapsed or refractory multiple myeloma across sites in Australia, Belgium, Denmark, France, Italy, New Zealand, South Korea, Spain, and the United Kingdom.
Forimtamig is being developed by Roche Holding AG, which trades on the OTC market under the ticker RHHBY. Roche is the sponsor of the clinical program evaluating the drug in multiple myeloma.
Forimtamig is in Phase 1 clinical development. One Phase 1 trial has been completed, and no active trials are currently listed. The completed study was a controlled, randomized, non-double-blind trial that enrolled 225 participants with relapsed or refractory multiple myeloma.
Forimtamig has been evaluated in one completed Phase 1 trial, NCT04557150, titled A Study Evaluating the Safety and Pharmacokinetics of Escalating Doses of Forimtamig in Participants With Relapsed or Refractory Multiple Myeloma. The trial enrolled 225 adults aged 18 years and older, across both sexes, and was conducted in nine countries.
Forimtamig is not FDA approved. It is an investigational drug still in clinical development, with only a completed Phase 1 trial in relapsed or refractory multiple myeloma. No regulatory approval has been granted for any indication.